Cargando…
Immunotherapy and Immune Evasion in Prostate Cancer
Metastatic prostate cancer remains to this day a terminal disease. Prostatectomy and radiotherapy are effective for organ-confined diseases, but treatment for locally advanced and metastatic cancer remains challenging. Although advanced prostate cancers treated with androgen deprivation therapy achi...
Autores principales: | Thakur, Archana, Vaishampayan, Ulka, Lum, Lawrence G. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3730318/ https://www.ncbi.nlm.nih.gov/pubmed/24216992 http://dx.doi.org/10.3390/cancers5020569 |
Ejemplares similares
-
Phase I Study of Anti-CD3 x Anti-Her2 Bispecific Antibody in Metastatic Castrate Resistant Prostate Cancer Patients
por: Vaishampayan, Ulka, et al.
Publicado: (2015) -
Development of cabozantinib for the treatment of prostate cancer
por: Vaishampayan, Ulka N
Publicado: (2014) -
Overcoming Obstacles in Liquid Biopsy Developments for Prostate Cancer
por: Jang, Albert, et al.
Publicado: (2022) -
Immune landscape of human prostate cancer: immune evasion mechanisms and biomarkers for personalized immunotherapy
por: Bou-Dargham, Mayassa J., et al.
Publicado: (2020) -
Immune disorder in endometrial cancer: Immunosuppressive microenvironment, mechanisms of immune evasion and immunotherapy
por: Zhan, Lei, et al.
Publicado: (2020)